OncoMatch/Clinical Trials/NCT05092451
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Is NCT05092451 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Cyclophosphamide and CAR.70/IL15-transduced CB-NK cells for b-cell lymphoma.
Treatment: Cyclophosphamide · CAR.70/IL15-transduced CB-NK cells · Fludarabine phosphate — The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Multiple Myeloma
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Chronic Myeloid Leukemia
Biomarker criteria
Required: CD70 expression ≥ 10% (≥ 10%)
expression of CD70 in the pre-enrollment tumor sample ≥ 10% measured by immunohistochemistry or flow cytometry
Prior therapy
Cannot have received: allogeneic stem cell transplant or donor lymphocyte infusion
Lab requirements
Kidney function
Serum creatinine ≤ 2x ULN or estimated Glomerular Filtration Rate ≥ 30 ml/min/1.73 m2
Liver function
ALT/AST ≤ 3 x ULN or ≤ 5 x ULN if documented liver metastases, Total bilirubin <2xULN, except in subjects with Gilbert's Syndrome in whom total bilirubin must be ≤ 3 x ULN. No history of liver cirrhosis. No ascites.
Cardiac function
Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion as determined by an ECHO, and no uncontrolled arrhythmias or symptomatic cardiac disease.
Adequate organ function: Renal: Serum creatinine ≤ 2x ULN or estimated Glomerular Filtration Rate ≥ 30 ml/min/1.73 m2; Hepatic: ALT/AST ≤ 3 x ULN or ≤ 5 x ULN if documented liver metastases, Total bilirubin <2xULN, except in subjects with Gilbert's Syndrome in whom total bilirubin must be ≤ 3 x ULN. No history of liver cirrhosis. No ascites. Cardiac: Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion as determined by an ECHO, and no uncontrolled arrhythmias or symptomatic cardiac disease. Pulmonary: No clinically significant pleural effusion (per PI discretion), baseline oxygen saturation > 92% on room air and adequate pulmonary function with FEV1, FVC and DLCO (corrected for Hgb) >50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify